GGrantIndex
Sort

17,288 grants matching multiple sclerosis

MRI Paramagnetic Rim Lesions as Biomarkers and Agents of Neurodegeneration in Multiple Sclerosis

$221,553
Christopher C. Hemond · Univ Of Massachusetts Med Sch Worcester · K23 · FY2024 · NS

Targeted Ion Channel Downregulation By Nanoparticles: A Novel Therapeutic approa

$221,444
Laura Conforti · University Of Cincinnati · R21 · FY2011 · AR

MOLECULAR BIOLOGY OF CONONAVIRUS INDUCED DEMYELINATION

$221,401
University Of Pennsylvania · R01 · FY2002 · NS

Multifunctional Biomaterial for Amelioration of MS in Murine EAE Model

$221,399
Julia E Babensee · Georgia Institute Of Technology · R21 · FY2016 · EB

NEUROPATHOLOGY

$221,375
Matthew P Frosch · Massachusetts General Hospital · P50 · FY2009 · AG

Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes

$221,331
Gregory Paul Marshall · Onevax, Llc · R43 · FY2018 · AI

INTERFERON GAMMA EFFECTS ON OLIGODENDROCYTES

$221,326
University Of North Carolina Chapel Hill · R01 · FY2000 · NS

Epigenomic regulation of oxidative stress-producing innate immunity in neuroinflammation

$221,306
Andrew S Mendiola · University Of California, San Diego · R00 · FY2025 · NS

Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2

$221,265
Daniel R Scoles · University Of Utah · R21 · FY2014 · NS

Regulation of Th17 immune responses by serpinB1

$221,250
Eileen Remold-O'Donnell · Boston Children'S Hospital · R21 · FY2017 · AI

Role of Caspase-8 in Neuroinflammation, Demyelination and Myelin Repair

$221,250
Jianrong Li · Texas A&M Agrilife Research · R21 · FY2015 · NS

Structure and function of peptide presentation by CD1d

$221,250
Dirk M Zajonc · La Jolla Institute For Immunology · R21 · FY2014 · AI

Inhibition of CD38 NADase by anti-CD38 antibody: a novel therapy for systemic scleroderma

$221,204
Willem Van Schooten · Teneobio, Inc. · R43 · FY2020 · AR

microRNA target site RNA-directed oligonucleotide topical therapeutics in psoriasis

$221,100
Jeffrey R. Bender · Yale University · R21 · FY2021 · AR

Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)

$221,036
Dorothy Anne Cross · Washington University · P01 · FY2009 · NS

Mechanisms underlying neuronal damage in EAE: role of microglia

$221,022
Stella Elkabes · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2007 · NS

GABA-B Receptor Modulation of Calcium Currents

$220,952
Michelle Mynlieff · Marquette University · R15 · FY2010 · NS

Elucidating the structure-function relationship of LARP6-mediated collagen mRNA transport

$220,945
Lisa R Warner · Boise State University · P20 · FY2021 · GM

Novel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple Sclerosis

$220,875
Mireia Guerau-De-Arellano · Ohio State University · R21 · FY2017 · AI

Genetic analysis of endocannabinoid signaling in C. elegans

$220,842
Shawn R Lockery · University Of Oregon · R21 · FY2019 · DA

Development of SAgA Therapy for clearance of NMO-IgG in patients with neuromyelit

$220,834
Joshua O Sestak · Orion Bioscience, Inc. · R43 · FY2014 · EY

Susceptibility MRI as a marker for diagnosis and clinical disability in MS

$220,821
Chunlei Liu · Duke University · R01 · FY2014 · NS

Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)

$220,819
Dorothy Anne Cross · Washington University · P01 · FY2011 · NS

The IRF - type I interferon system in T cell-mediated immune tolerance

$220,717
Michael David · University Of California, San Diego · R21 · FY2014 · AI

Stretchable electronic-bladder interface for neuroprosthetic control

$220,704
Timothy M. Bruns · University Of Michigan At Ann Arbor · R21 · FY2016 · EB